Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amgen, Inc. (AMGN), Baxter International Inc. (BAX): Can the FDA Make Up Its Mind Already?

It isn’t very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that’s exactly where the Food and Drug Administration finds itself. And this time the criticism is coming from pharmaceutical companies themselves. Companies developing generic biologic drugs, which are often costlier and more complicated to manufacture than small molecules, have only loose guidelines on what the agency wants to see for approval. Additionally, the Biosimilar User Fee Act of 2012 — meant to clarify development procedures — only made things worse.

Amgen, Inc. (NASDAQ:AMGN)

The problem gets even worse when you consider that the European Medicine Agency has a clear-cut roadmap for biosimilar drugs. In fact, more than a dozen of the generics have been approved on the continent. Why should cheaper treatments be available in one market and not another due to a simple lack of communication?

The market opportunity in the United States could be huge. Take a look at some of the top biosimilar companies waiting for the FDA to make up its mind.

  1. Amgen, Inc. (NASDAQ:AMGN) is looking to launch six biosimilars beginning in 2017 for drugs such as Herceptin, Humira, Remicade, and Rituxan. The company believes biosimilars represent a multibillion-dollar opportunity.
  2. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) and
    Baxter International Inc. (NYSE:BAX) are collaborating on up to six biosimilars for autoimmune diseases and oncology. Three have already been identified, and one should have an investigational new drug application submitted next year.
  3. Novartis AG (ADR) (NYSE:NVS) wants its generic business, Sandoz, to cement its role as a world-leading biosimilar company. Already controlling half of the global biosimilar market, Sandoz is currently developing 10 molecules to add to its portfolio.
  4. Hospira, Inc. (NYSE:HSP) offers services ranging from contract manufacturing to software, but it, too, wants to add a biosimilar program. The company is developing generic versions of Epogen, Herceptin, Neulasta, Neupogen, and Remicade.

There is a lot at stake, and plenty of companies that are nudging the FDA clear things up. In the following video, Fool contributor Maxx Chatsko breaks down the industry’s frustration and what can be done to resolve the issue.

The article Can the FDA Make Up Its Mind Already? originally appeared on is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool recommends Momenta Pharmaceuticals (NASDAQ:MNTA). The Motley Fool owns shares of Momenta Pharmaceuticals.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.